GT Biopharma Receives FDA Clearance to Commence First-in-Human Phase 1 Study of its First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550, for the Treatment of Acute Myelogenous Leukemia, Myelodysplatic Syndrome and Mastocytosis
November 01, 2018 09:30 ET
|
GT Biopharma, Inc.
LOS ANGELES, Nov. 01, 2018 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (OTCQB: GTBP and Euronext Paris GTBP.PA) ("GT Biopharma" or the "Company"), an immuno-oncology biotechnology company focused on...
GT Biopharma, Inc. Files Application for NASDAQ Capital Market Listing
December 18, 2017 10:47 ET
|
GT Biopharma, Inc.
WASHINGTON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- GT Biopharma Inc. (OTCQB:GTBP) today announced that the Company has filed an application to list its common stock on the NASDAQ Capital Market. GT...